Delayed Sodium Thiosulfate as an Otoprotectant Against Carboplatin-induced Hearing Loss in Patients with Malignant Brain Tumors


Departments of Neurology [N. D. D., L. L. M., R. M. T., C. L., E. A. N.], Pharmacology [R. E. B., J. S. B.], Otolaryngology [R. E. B.], Medicine [M. C. H.], Divisions of Medical Informatics and Outcomes Research [D. F. K.], Hematology and Medical Oncology [M. C. H.], Oregon Health Sciences University, and Research Service [E. A. N.], and Rehabilitation Research and Development Service, National Center for Rehabilitative Auditory Research [J. A. H.], Veterans Affairs Medical Center [M. C. H., J. A. H., E. A. N.], Portland, Oregon 97201

ABSTRACT

Carboplatin is effective in the treatment of malignant brain tumors. However, when administered in conjunction with osmotic opening of the blood-brain barrier (BBB), carboplatin is ototoxic. The purpose of this study was to determine whether delayed administration of sodium thiosulfate (STS), given after BBB closure, provided protection against carboplatin ototoxicity. Patients underwent monthly treatment with intra-arterial carboplatin (200 mg/m²/day x 2) in conjunction with osmotic opening of the BBB, for up to 1 year. Audiological assessment was conducted at baseline and within 24 h before each monthly treatment. STS was administered i.v. as one (20 g/m²) or two (20 g/m² and 16 g/m²) 15-min doses, depending on baseline hearing status. The initial group received the first STS dose 2 h (or 2 and 6 h) after carboplatin (STS2) and a subsequent group received STS 4 h (or 4 and 8 h) after carboplatin (STS4). Audiological data were compared with a historical comparison group (HCG) treated with carboplatin without STS. Spearman correlation coefficients comparing STS 2 (n = 24), STS4 (n = 17), and HCG (n = 19) indicated significantly lower rates of ototoxicity with increased delay in STS (P = 0.0006). On the basis of the analysis of hearing levels, there were significant differences among the two STS groups and HCG at 8000 Hz (P = 0.0010) and at 4000 Hz (P = 0.0075). The log-rank test for time to ototoxicity indicated a significant difference between STS4 and HCG (P = 0.0018). Delayed STS was effective in protecting against carboplatin-induced hearing loss. STS delayed to 4 h after carboplatin significantly decreased time to development of ototoxicity and rate of ototoxicity when compared with HCG.

INTRODUCTION

Platinum chemotherapy agents have shown efficacy in both systemic and CNS malignancies (1). Cisplatin [cis-diaminedichloroplatinum(II)] is an effective drug in head and neck (2, 3), lung (4–6), ovarian (7, 8), and testicular (9) cancer. Dose-limiting effects associated with cisplatin include severe renal, neurological, and auditory toxicity. Although cisplatin nephrotoxicity may be avoided with hydration and diuresis (4), ototoxicity remains an irreversible, dose-limiting side effect of this drug (10–16). The reported incidence of cisplatin-induced hearing loss ranges from 4–91% (17, 18).

Carboplatin [cis-diamine (1, 1-cyclobutane-dicarboxylato) platinum(II)], an analogue of cisplatin, was introduced in the early 1980s to help avoid some of the toxicities of cisplatin. It has been suggested that carboplatin is equivalent to cisplatin in the treatment of suboptimally debulked ovarian cancer, extensive-stage small cell lung cancer, and non-small cell lung cancer (4). Additionally, carboplatin is effective in the treatment of malignant brain tumors (19–21). The delivery of carboplatin-based therapy in conjunction with osmotic opening of the BBB has shown efficacy in single- (22, 23) as well as multi-institutional (24) studies, particularly in astrocytoma, PNET, germ cell tumor, and CNS metastases. Osmotic BBBD is induced by a 30-second i.a. infusion of 25% mannitol into a selected internal carotid or vertebral artery, depending on tumor location (25, 26). By transiently opening the BBB, this technique creates a two-compartment model, as well as providing the opportunity to increase chemotherapy delivery to the CNS (25).

Carboplatin-induced ototoxicity has been reported by several investigators (17, 22, 27–29). Parsons et al. (28) noted ototoxicity in 9 of 11 (82%) of children with neuroblastoma treated with autologous bone marrow transplantation when car-

Received 8/28/00; revised 12/13/00; accepted 12/15/00.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

This work was supported by a Veterans Administration Merit Review Grant, and NIH R01 Grants CA 31770, from the National Cancer Institute, and NS 33618 and NS 34608 from the National Institute of Neurological Disorders and Stroke.

2 To whom requests for reprints should be addressed, at Oregon Health Sciences University, 3181 SW Sam Jackson Park Road-L603, Portland, OR 97201-3098. Phone: (503) 494-5626; Fax: (503) 494-5627; E-mail: neuwelt@ohsu.edu.

The abbreviations used are: CNS, central nervous system; i.a., intra-arterial; BBB, blood-brain barrier; BBBD, blood-brain barrier disruption; STS, sodium thiosulfate; PNET, primitive neuroectodermal tumor; HCG, historical comparison group; dB, decibel; HL, hearing level; ANCOVA, analysis of covariance; RICA, right internal carotid artery; SD, stable disease.

Downloaded from clincancerres.aacrjournals.org on April 14, 2017. © 2001 American Association for Cancer Research.
boplatin was part of their conditioning regimen. We reported otoxicity when carboplatin was administered across an open BBB, particularly in the vertebral artery circulation (22, 27).

Hearing loss negatively affects quality of life. Children undergoing treatment with platinum chemotherapy are at risk for otoxicity (28), which can delay development of language and reading skills (30). Studies in elderly individuals document depressive symptomatology in the hearing-impaired (31, 32). In an attempt to ameliorate this problem, several thiols-containing compounds have been studied for potential otoprotective activity against cisplatin. Although amifostine (33, 34) has shown efficacy in decreasing cisplatin-induced nephrotoxicity, its otoprotective effect is unclear. In animal models, L-methionine (10, 11) reduced the hearing loss caused by high-dose cisplatin, however this agent has not yet been tested in clinical trials. On the basis of encouraging results in animal models (35), we conducted a Phase I clinical study in 1996 to determine a safely tolerated dose of STS (American Regent Laboratories, Inc., Shirley, NY) and to obtain preliminary data on the otoprotective effect of STS against carboplatin-induced ototoxicity (27). Patients were treated with a two-route, two-compartment model. That is, carboplatin was administered i.a. within 5 min after osmotic opening of the BBB. Two h after carboplatin, when BBB permeability generally returned to baseline, creating two compartments, STS was administered i.v. The maximum tolerated dose of STS was 20 g/m² (27).

A key concern is the potential effect of STS on platinum efficacy against tumor. In CNS malignancies, the creation of a two-compartment model by BBBD, should minimize this effect through administration of STS after BBB closure. This two-compartment model and the high ratio of STS:carboplatin required to inactivate carboplatin (27, 35–37) suggest it is unlikely that STS interferes with the cytotoxic effects of CNS drug. However, in non-CNS malignancies, the effect of STS on platinum cytoreduction remains a problem. One alternative to avoid the negative interactions of platinum chemotherapeutics and STS is to delay the administration of STS. In laboratory studies of a nude rat model of human small cell carcinoma grown subcutaneously, delayed administration of STS (e.g., to 8 h) did not impact the efficacy of carboplatin (38). The purpose of the present clinical study was to describe the differences in hearing protection in patients with malignant brain tumors when STS administration was delayed from 2 h to 4 h after carboplatin with BBB opening, compared with a HCG of patients treated with carboplatin with BBB opening who did not receive STS.

**MATERIALS AND METHODS**

The study was approved by the Institutional Review Board of the Oregon Health Sciences University. Informed consent was obtained from each patient or from the patient’s legal guardian, in accordance with institutional regulations.

**Audiological Assessment.** Patients generally underwent carboplatin treatment administered with osmotic opening of the BBB monthly on 2 consecutive days for up to 1 year. As patients entered the protocol, before treatment with carboplatin, they were required to undergo baseline audiological assessment. The assessment included air- and bone-conduction pure-tone thresholds of hearing sensitivity (250 to 8000 Hz). Patients underwent audiograms monthly within 24 h before each treatment with carboplatin.

**Chemotherapy Regimen.** BBB opening was performed with the patient under general anesthesia as described previously (39). Depending on the location of the tumor, 25% mannitol was infused (5–10 ml/sec) into the appropriate internal carotid or vertebral artery, for 30 seconds. The combination chemotherapy regimen consisted of i.v. cyclophosphamide (330 mg/m²/day × 2 days; total dose, 660 mg/m²) beginning ~20 min before the mannitol infusion. Carboplatin (200 mg/m²/day × 2 days; total dose, 400 mg/m²) was infused i.a. over 10 min, starting within 5 min after the mannitol. Additionally, patients received either i.a. or i.v. etoposide phosphate (200 mg/m²/day × 2 days; total dose, 400 mg/m²).

**Dose and Timing of STS.** STS was available as a 25% (250 mg/ml) solution. Patient dose was determined (16 or 20 g/m²) and mixed with an equivalent amount of normal saline (1:1) for infusion. Because high-dose STS (16 or 20 g/m²) causes transient hypernatremia, hypertension, and controllable grade II nausea and vomiting (National Cancer Institute Common Toxicity Criteria, version 2.0), patients were premedicated with antiemetics before STS (27). The most commonly used antiemetic regimen consisted of benadryl (12.5 mg), dexamethasone (6 mg), and, if needed, ativan (0.5–1.0 mg), given i.v. 30–45 min before STS.

STS was administered i.v. over 15 min. Initially, patients were treated with one dose of STS 2 h after carboplatin (27). Because 50% of patients with impaired baseline hearing developed an additional 20-dB threshold shift, it was clear that one dose of STS was insufficient to prevent otoxicity (40) in these patients. Therefore, in August 1997, patients with good to excellent baseline hearing sensitivity (thresholds <20 dB HL at all frequencies within the range of 250-8000 Hz) continued to receive one dose of STS (20 g/m²) 2 h after carboplatin. Patients with impaired baseline hearing (thresholds >20 dB HL at one frequency and/or >15 dB HL at two consecutive frequencies, within the range of 250-8000 Hz) received one dose of STS (20 g/m²) 2 h after carboplatin and a second dose (16 g/m²) 6 h after carboplatin. Patients with good to excellent baseline hearing who sustained an ototoxic shift (>20 dB threshold shift at any frequency, ≥10 dB shift at two adjacent test frequencies, or loss of response at three consecutive test frequencies where responses were obtained at baseline; Ref. 40) during the year-long carboplatin treatment thereafter received the two-dose STS regimen.

Through March 1998, patients received the first STS dose 2 h after carboplatin. In April 1998, after discussions with several investigators using osmotic opening of the BBB to treat patients with malignant brain tumors, the decision was made to allow a greater delay between opening the BBB and administering STS. The reason for this decision was data suggesting a greater time of increased barrier permeability after osmotic opening than was previously thought (26). Thereafter, administration of STS was delayed to 4 h after carboplatin. Patients with good to excellent baseline hearing received one dose of STS 4 h after carboplatin. Patients with impaired baseline hearing and patients who sustained an ototoxic shift during treatment (40) received the first dose of STS 4 h after carboplatin and the second dose of STS 8 h after carboplatin. The extended time of increased barrier permeability after osmotic opening than was previously thought (26). Thereafter, administration of STS was delayed to 4 h after carboplatin. Patients with good to excellent baseline hearing received one dose of STS 4 h after carboplatin. Patients with impaired baseline hearing and patients who sustained an ototoxic shift during treatment (40) received the first dose of STS 4 h after carboplatin and the second dose of STS 8 h after carboplatin. The extended time
appeared justified based on data from our animal model sug-
gesting that STS would minimize ototoxicity even when admin-
istered 8 h or more after carboplatin (38).

Data Analysis. Audiological data collected through mid-
August 1999 were included in the statistical analysis. Data were
analyzed in three treatment groups: the HCG, patients treated
with STS at 2 (or 2 and 6) h after carboplatin (STS2), and
patients treated with STS at 4 (or 4 and 8) h after carboplatin
(STS4). For patients who changed from the 2-h to the 4-h STS
protocol midway through the year-long carboplatin treatment,
audiological data obtained during treatment with the 2-h STS
protocol were included in STS2. Audiological data obtained
after patients changed to the 4-h STS protocol were not included
in the statistical analysis.

Two patients with impaired baseline hearing treated with
the 2-h STS protocol were initially treated with one dose of STS
but subsequently received two doses of STS. Because the first
dose of STS was administered at 2 h, for the purposes of
analysis these two patients were included in the STS2 group.
Additionally, two patients were treated with one course of the
2-h STS protocol but subsequently, for the remainder of their
carboplatin treatments, received the 4-h STS protocol. For the
purposes of analysis, these two patients were included in the
STS4 group.

Hearing levels were compared using a repeated-
treatments ANCOVA model. Baseline hearing levels and
treatment number were fit as continuous variables, whereas
treatment group and ear and audiometric test frequency were
fit as factors. Various interactions among the factors and
between factors and the continuous variables were also fit. A
mixed-model approach (41) was used to perform these anal-
yses. Three different correlation structures (autoregressive
moving average, first-order autoregressive, and compound
symmetry) were fit in each case, and the best model was
selected using Akaike's information criterion. Because the
full ANCOVA model included several significant interac-
tions involving frequency, separate models (that is, frequency-
specific models) were fit to better assess the associations
in the full ANCOVA model. Least-squares means allow
comparisons among mean values adjusted for other factors in
a model. Comparisons among least-squares means are made
with Tukey-Kramer adjustments for multiple comparisons.
All analyses were performed using version 7.0 of SAS for
Windows 95 (42).

As discussed in the results, frequency-specific ANCOVA
models were also fit to these data. To maintain the overall
significance level at the nominal level of 0.05, the P for these
frequency-specific models should be compared with a Bonferroni-adjusted (43) significance level of 0.0083 (0.05 divided by
6, the number of test frequencies).

The number of treatments until ototoxicity occurred was
estimated using Kaplan-Meier estimation, and these values were
plotted as a function of treatment number. The log-rank test was
used to compare the distributions of time with ototoxicity
among the three treatment groups (44). Because a significant
difference among the three groups did not specify which pairs of
treatment groups are different, pairwise comparisons among the
three treatment groups (with Bonferroni-adjusted significance
level of 0.0167 for three pairs of comparisons) were run as
needed. A Spearman rank correlation (43) was computed to
compare ototoxicity with the ordered treatment groups (HCG,
STS2, and STS4).

RESULTS

HCG. Between February 1992 and May 1995, 37 pa-
tients underwent treatment with carboplatin in conjunction
with osmotic opening of the BBB in a representa-
tive patient in the HCG who did not receive STS. The baseline
audiogram (May 19, 1993) from the right ear obtained before initiating
carboplatin treatment and subsequent audiograms obtained after initiating
carboplatin treatment (June 28, 1993 and October 4, 1993) are
shown.

Fig. 1 Patient audiogram showing hearing loss after carboplatin ad-
ministered in conjunction with osmotic opening of the BBB in a re-
presentative patient in the HCG who did not receive STS. The baseline
 audiogram (May 19, 1993) from the right ear obtained before initiating
carboplatin treatment and subsequent audiograms obtained after initiating
carboplatin treatment (June 28, 1993 and October 4, 1993) are
shown.

STS Treatment Groups. Forty-one patients were treated
with high-dose STS in conjunction with 454 carboplatin treat-
ments. Patient characteristics are listed in Table 1. Eleven (46%)
of the patients in STS2 and four (24%) of the patients in STS4
had a history of radiation treatment that occurred before the
determination of baseline hearing sensitivity thresholds for this
study. Twenty-four patients were treated with the 2- h STS protocol (STS2). This group underwent 271 carboplatin
 treatments with 96 infusions in the vertebral arteries. Seventeen patients were treated with the 4- h STS protocol (STS4) and underwent 183 carboplatin treatments with
47 infusions in the vertebral arteries. Table 2 shows the number of patients in the HCG, STS2, and STS4 groups at each monthly
carboplatin treatment. Four patients in STS4 were in the midst of the year-long carboplatin treatment at the time of the cutoff for data analysis.

Two-compartment Model. Fig. 2A and B, illustrate the two-compartment model created by transiently opening the BBB. Fig. 2A shows a 99mTc-glucopentate radionuclide brain scan with isotope given 5 min after the delivery of hypertonic mannitol into the RICA, illustrating the BBB opening in the right cerebral hemisphere. A computed tomography scan obtained in the same patient with iodinated contrast given 60 min after mannitol (Fig. 2B) shows minimal contrast enhancement in the disrupted hemisphere, illustrative of a barrier that has almost completely returned to baseline permeability by 1 hour. Carboplatin was administered i.a. immediately after osmotic opening of the BBB, thus crossing the opened BBB. STS was then administered i.v. 2 or 4 h after BBBD, after BBB permeability generally returned to baseline levels. Pollay et al. (45) reported previously that the highly charged STS molecule does not cross the BBB.

Efficacy of STS in Maintaining Hearing Sensitivity. The full repeated-measures ANCOVA model had several significant three-way interactions involving test frequency. For this reason, frequency-specific models were fit to better understand any group differences. At 8000 Hz and at 4000 Hz, after adjusting for baseline hearing levels, there were significant differences among the treatment groups ($P = 0.0010$ and $P = 0.0075$, respectively) and significant linear ($P = 0.0002$ and $P = 0.0001$, respectively) and quadratic trends (at 4000 Hz only; $P = 0.035$) with treatment. The least-squares means (see “Materials and Methods”) for treatment groups (in order: 4-h protocol, 2-h protocol, and historical comparison) were 34.1 dB, 41.7 dB, and 64.4 dB at 8000 Hz and 28.6 dB, 35.4 dB, and 51.6 dB at 4000 Hz. There were significant differences between each of the STS groups and the historical comparisons, but no significant differences between the two STS groups. For the 1000 and 2000 Hz frequencies, there were no significant differences among the treatment groups once the Bonferroni adjustment was used. For 500 and 250 Hz, after adjustment for baseline hearing levels, there were no significant treatment effects.

Table 1 Patient characteristics

<table>
<thead>
<tr>
<th>HCG</th>
<th>STS2</th>
<th>STS4</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients (%)</td>
<td>No. of patients (%)</td>
<td>No. of patients (%)</td>
</tr>
<tr>
<td>Total patients</td>
<td>19</td>
<td>24</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>11 (58)</td>
<td>11 (46)</td>
</tr>
<tr>
<td>Female</td>
<td>8 (42)</td>
<td>13 (54)</td>
</tr>
<tr>
<td>Prior treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>7 (37)</td>
<td>9 (38)</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>5 (21)</td>
<td>11 (46)</td>
</tr>
<tr>
<td>Age (yr)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>30</td>
<td>43.5</td>
</tr>
<tr>
<td>Minimum</td>
<td>8</td>
<td>11</td>
</tr>
<tr>
<td>Maximum</td>
<td>67</td>
<td>66</td>
</tr>
<tr>
<td>No. of patients ≤18 yr</td>
<td>2 (10)</td>
<td>3 (13)</td>
</tr>
<tr>
<td>KPS&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>90</td>
<td>80</td>
</tr>
<tr>
<td>Minimum</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>Maximum</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Tumor classification</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primitive neuroectodermal tumor</td>
<td>7 (37)</td>
<td>4 (17)</td>
</tr>
<tr>
<td>Astrocytoma</td>
<td>2 (10)</td>
<td>4 (17)</td>
</tr>
<tr>
<td>Glioblastoma</td>
<td>3 (16)</td>
<td>2 (8)</td>
</tr>
<tr>
<td>Metastatic cancer to the brain</td>
<td>4 (21)</td>
<td>1 (4)</td>
</tr>
<tr>
<td>Relapsed CNS lymphoma</td>
<td>1 (5)</td>
<td>2 (8)</td>
</tr>
<tr>
<td>Oligoastrocytoma</td>
<td>0 (0)</td>
<td>4 (17)</td>
</tr>
<tr>
<td>Oligodendrogloma</td>
<td>0 (0)</td>
<td>2 (8)</td>
</tr>
<tr>
<td>Anaplastic oligodendrogloma</td>
<td>0 (0)</td>
<td>1 (4)</td>
</tr>
<tr>
<td>Brain stem glioma</td>
<td>1 (5)</td>
<td>2 (8)</td>
</tr>
<tr>
<td>Optic glioma</td>
<td>0 (0)</td>
<td>2 (8)</td>
</tr>
<tr>
<td>Retinoblastoma</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Germ cell</td>
<td>1 (5)</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

<sup>a</sup> KPS: Karnofsky Performance Status.

Table 2 Number of patients in each group at each treatment

<table>
<thead>
<tr>
<th>Treatment no.</th>
<th>HCG (n = 19)</th>
<th>STS2 (n = 24)</th>
<th>STS4 (n = 17)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>19</td>
<td>24</td>
<td>17</td>
</tr>
<tr>
<td>2</td>
<td>19</td>
<td>19</td>
<td>15</td>
</tr>
<tr>
<td>3</td>
<td>17</td>
<td>17</td>
<td>11</td>
</tr>
<tr>
<td>4</td>
<td>17</td>
<td>15</td>
<td>8</td>
</tr>
<tr>
<td>5</td>
<td>14</td>
<td>14</td>
<td>8</td>
</tr>
<tr>
<td>6</td>
<td>11</td>
<td>11</td>
<td>7</td>
</tr>
<tr>
<td>≥7</td>
<td>9</td>
<td>9</td>
<td>6</td>
</tr>
</tbody>
</table>
HCG, STS2, and STS4. There was a significant difference between the STS treatment groups and the HCG ($P = 0.0075$).

**Delay in Onset of Ototoxicity.** The Kaplan-Meier estimates of the time to ototoxicity are plotted against treatment in Fig. 4. There is a significant difference among the three treatment groups using the log-rank test ($P = 0.0069$). The difference between the 4-h protocol and the historical comparisons is statistically significant ($P = 0.0018$), whereas the differences between the 2-h protocol and the historical comparisons ($P = 0.0730$) and the 2-hour protocol and the 4-hour protocol ($P = 0.12$) are not significant. These $P$s need to be compared with a significance level of 0.0167, as described in “Materials and Methods.”

Over the study period, 84% of the historical comparisons experienced ototoxicity, whereas only 54% of the patients on the 2-h protocol and 29% of the patients on the 4-hour protocol experienced ototoxicity. The Spearman correlation coefficient comparing the ordered treatment groups with ototoxicity or not yielded a correlation of $-0.43$ ($P = 0.0006$). These analyses illustrate significantly lower rates of ototoxicity as one progresses from no STS to an STS 2-h protocol to an STS 4-h protocol.

**DISCUSSION**

**Potential for Delayed STS in CNS and Non-CNS Tumors.** Otoprotection in patients undergoing carboplatin treatment in conjunction with osmotic opening of the BBB can be achieved with high-dose STS administered 2 or 4 h after carboplatin. The greater the delay in STS administration (from HCG to STS2 to STS4), the lower the rate of ototoxicity ($P = 0.0006$). There is a significant difference between STS administered at 4 h and the HCG, with respect to time to ototoxicity and maintenance of hearing sensitivity at 8000 Hz ($P = 0.0010$) and 4000 Hz ($P = 0.0075$) and a trend toward differences between STS administered at 2 h and at 4 h in delaying ototoxicity and in maintaining hearing sensitivity, however the sample size is not large enough to demonstrate statistical significance.

The efficacy of delayed STS administration is important.
Muldoon et al. (38) reported that, in an animal model, delayed administration of STS up to 8 h after carboplatin reduced ototoxicity without reducing the antitumor cytotoxicity of carboplatin. If STS prevents ototoxicity in patients at even later time points (e.g., 8 h) than in this clinical study, treatment with STS may be applicable both to other platinum agents such as cisplatin and to non-CNS tumors. Eight-hour delayed administration of STS would ensure adequate time for non-CNS platinum cytotoxicity to occur. To test such a hypothesis, our group has developed a clinical protocol for children undergoing cisplatin treatment for osteosarcoma, germ cell tumor, PNET, and neuroblastoma. In addition, although carboplatin does not have equivalent activity to cisplatin in all platinum-sensitive tumors, carboplatin use is increasing in some cancers [suboptimally debulked ovarian cancer and non-small cell and extensive-stage small cell lung cancer (4)] because of similar efficacy and fewer toxic attributes, and higher doses of carboplatin are being used to increase antitumor efficacy (28, 46). As carboplatin doses are intensified, the incidence of ototoxicity must be closely monitored.

Effect of STS on Carboplatin Cytotoxicity. Despite a two-compartment model and the high ratio of STS:carboplatin required to inactivate carboplatin (27, 35–37), the possibility remains that STS reduces carboplatin tumoricidal effect. Because of the varying CNS tumor histologies and the small number of patients within each histological category in HCG, STS2, and STS4 (Table 1), it is not yet possible to determine whether or not there is an effect of STS on clinical outcomes such as tumor response. We continue to closely monitor response rates. For example, patients in STS2 and STS4 with PNET (n = 5), astrocytoma (n = 7), and glioblastoma (n = 5) had the following tumor responses: (a) PNET: one complete response, three partial responses, and one SD; (b) astrocytoma: three partial responses and four SDs; (c) glioblastoma: four SDs, 1 progressive disease. In the future, with a larger series of patients with more homogenous CNS malignancies and with continued monitoring of tumor responses, a more definitive analysis of the effect of STS on clinical outcomes will be possible.

Quality of Life. Loss of pure-tone sensitivity in the 2000–4000 Hz frequency range results in difficulty discriminating consonant sounds. This difficulty is exacerbated when attempting to identify words in the presence of background noise (28). Hearing loss exceeding 20 dB HL in the speech frequencies thus impacts family and social interaction as well as work status. Children with hearing impairment are at risk for problems with learning and communication (30). In the pediatric population, with loss of sensitivity in the 2000–4000 Hz range, a hearing aid is often required to optimize learning skills. In the hearing-impaired elderly population, studies have documented impairment in functional status, cognitive status, depressive symptomatology, and disability (31, 32).
Maximizing quality of life is essential in patients with limited survival. Strategies to achieve dose intensification and maximum cytotoxicity necessitate interventions to minimize the associated toxicities and to protect against untoward side effects of effective chemotherapeutics. Given the impact of hearing loss on quality of life in patients undergoing platinum chemotherapy, identification of agents to decrease ototoxicity is essential. We propose that clinical trials to evaluate 8-h delayed administration of STS in children, and subsequently in adults, undergoing cisplatin chemotherapy for non-CNS as well as CNS tumors may extend these positive results.

ACKNOWLEDGMENTS

We thank the following audiologists who provided timely and comprehensive assessment of all patients: Tori Blomquist, Rhonda Dojan, Sherry Dickie, Alexandra Hatton, Scott Hayes, Amy Johnson, Dan McDermott, and Natasha Podratz. We also thank the oncology nurses on 5A/C at Oregon Health Sciences University Hospital for coordinating STS dosing regimens, Jennifer Quipotla and Gail Campagna for expert editorial assistance, and Rhonda Dojan and Helen Klefner for data management.

REFERENCES


Delayed Sodium Thiosulfate as an Otoprotectant Against Carboplatin-induced Hearing Loss in Patients with Malignant Brain Tumors

Nancy D. Doolittle, Leslie L. Muldoon, Robert E. Brummett, et al.


Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/7/3/493

This article cites 41 articles, 10 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/7/3/493.full.html#ref-list-1

This article has been cited by 8 HighWire-hosted articles. Access the articles at:
/content/7/3/493.full.html#related-urls

Sign up to receive free email-alerts related to this article or journal.

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.